ChemMedChem

SJR Rank #8,691H-index: 130SJR: 0.670Best quartile: Q1APC: US$4,150
Journal website: aims, scope and author guidelines
Publisher

John Wiley and Sons Ltd

Country

United Kingdom

Type

journal

SJR by Edition

2022202500.20.40.60.8

Subject Categories

  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)Q1
  • BiochemistryQ2
  • Drug DiscoveryQ2
  • Organic ChemistryQ2
  • PharmacologyQ2
  • Molecular MedicineQ3

Areas: Biochemistry, Genetics and Molecular Biology · Chemistry · Pharmacology, Toxicology and Pharmaceutics

Most published research topics

Computational Drug Discovery MethodsClick Chemistry and ApplicationsChemical Synthesis and AnalysisSynthesis and biological activityHIV/AIDS drug development and treatmentSynthesis and Biological EvaluationPeptidase Inhibition and AnalysisCancer therapeutics and mechanismsReceptor Mechanisms and SignalingBiochemical and Molecular Research

Source: OpenAlex

Publication Statistics

2025 Docs3-Year DocsCitable Docs0200400600800

Documents per Year

20222025090180270360

Detailed Information

ISSN

1860-7187, 1860-7179

SJR Best Quartile

Q1

Region

Western Europe

Citations per Document (2 years)

3.47

References per Document

58.54

Coverage

2006-2026

Scope

Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies. ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs. Contents ChemMedChem publishes an attractive mixture of: Full Papers and Communications Reviews and Minireviews Patent Reviews Highlights and Concepts Book and Multimedia Reviews.

Metrics from SCImago Journal Rank 2025. View on SCImago